Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 maintenance olaparib vs placebo in platinum-sensitive relapsed BRCA-mutated ovarian cancer
jRCT2080222310Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in High-Grade Serous Ovarian Cancer (HGSOC), primary peritoneal cancer (PPC), fallopian tube cancer (PFTC) and 1 more comparing Olaparib maintenance with Placebo (2 arms). Started Nov 2013; status: completed.
02
Drugs
olaparib
03
Conditions
High-Grade Serous Ovarian Cancer (HGSOC)primary peritoneal cancer (PPC)fallopian tube cancer (PFTC)Endometrioid Cystadenocarcinoma
Beyond the preview
Go deeper on jRCT2080222310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222310.